Rhythm Biosciences jumps on Australian launch of blood test for bowel cancer
Rhythm Biosciences’ share price has jumped after announcing the start of commercialisation for ColoSTAT in Australia, its flagship blood-based colorectal cancer (CRC) test.
Rhythm starts commercialisation in Australia of its flagship blood test for bowel cancer ColoSTAT
The launch follows renewal of its ISO accreditation, marking its transition to its first market launch
ColoSTAT will initially be offered as a blood-based diagnostic alternative for symptomatic individuals
Special Report: Rhythm Biosciences surged more than 30% on Friday after confirming the commercial launch of its ColoSTAT blood test in Australia, enabled by its renewed ISO accreditation.
Rhythm Biosciences (ASX:RHY) said ColoSTAT would initially be offered for use in individuals who exhibit symptoms consistent with colorectal cancer (CRC), particularly where stool-based testing (the FIT test) is unsuitable or not preferred.
The predictive cancer diagnostics technology company said this approach would provide clinicians with an alternative pathway during periods of watchful waiting or in circumstances where stool-based screening cannot be completed.
Commercialisation will begin with the ColoSTAT Access Program which will include selected clinical leaders who will be supported by Rhythm to offer ColoSTAT to symptomatic individuals.
The initiative is designed to support clinician experience with the test, generate additional real-world data, and further strengthen the existing evidence base as Rhythm prepares for broader market penetration.
ColoSTAT will be provided as a clinical laboratory service through Rhythm’s Melbourne-based certified laboratory, with domestic market rollout and clinician activities starting immediately.
Consistent with its commitment to quality and regulatory compliance, Rhythm said it would undergo a National Association of Testing Authorities (NATA) review on January 23, 2026, to add ColoSTAT to its accredited testing services.
If approved, ColoSTAT would become an officially accredited test, helping build clinician confidence and supporting wider commercial scale-up.
Launch of ColoSTAT ends 2025 on a high
Rhythm chairman Gavin Fox-Smith said the launch of ColoSTAT in Australia marked a strong end to 2025.
“Initiating the commercialising of ColoSTAT before the end of 2025 has been a consistent and visible milestone communicated by the team and I’m delighted to see the business continue to meet its commitments,” he said.
CEO and managing director Dr David Atkins said the launch of ColoSTAT in Australia was in keeping with the company’s mission to detect cancer at the earliest possible stage, reducing the global burden of the disease and saving lives.
“This is welcome news for the many individuals in Australia who are unable or unwilling to use the current gold standard for bowel cancer detection,” he said.
This article was developed in collaboration with Rhythm Biosciences, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Originally published as Rhythm Biosciences jumps on Australian launch of blood test for bowel cancer
